Differential gene expression in ovarian carcinoma: Identification of potential biomarkers

Kathleen Hibbs, Keith M. Skubitz, Stefan E. Pambuccian, Rachael C. Casey, Kathryn M. Burleson, Theodore R. Oegema, Jeannine J. Thiele, Suzanne M. Grindle, Robin L. Bliss, Amy P.N. Skubitz

Research output: Contribution to journalArticlepeer-review

211 Scopus citations


Ovarian cancer remains the fifth leading cause of cancer death for women in the United States. In this study, the gene expression of 20 ovarian carcinomas, 17 ovarian carcinomas metastatic to the omentum, and 50 normal ovaries was determined by Gene Logic Inc. using Affymetrix GeneChip HU_95 arrays containing ∼12,000 known genes. Differences in gene expression were quantified as fold changes in gene expression in ovarian carcinomas compared to normal ovaries and ovarian carcinoma metastases. Genes up-regulated in ovarian carcinoma tissue samples compared to more than 300 other normal and diseased tissue samples were identified. Seven genes were selected for further screening by immunohistochemistry to determine the presence and localization of the proteins. These seven genes were: the β8 integrin subunit, bone morphogenetic protein-7, claudin-4, collagen type IX α2, cellular retinoic acid binding protein-1, forkhead box J1, and S100 calcium-binding protein Al. Statistical analyses showed that the β8 integrin subunit, claudin-4, and S100A1 provided the best distinction between ovarian carcinoma and normal ovary tissues, and may serve as the best candidate tumor markers among the seven genes studied. These results suggest that further exploration into other up-regulated genes may identify novel diagnostic, therapeutic, and/or prognostic biomarkers in ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)397-414
Number of pages18
JournalAmerican Journal of Pathology
Issue number2
StatePublished - Aug 2004

Bibliographical note

Funding Information:
Supported by grants from the Department of the Army ( DA/DAMD17-99-1-9564 ), the National Institutes of Health/National Cancer Institute ( CA0913825 ), the Minnesota Medical Foundation, and the Minnesota Ovarian Cancer Alliance.


Dive into the research topics of 'Differential gene expression in ovarian carcinoma: Identification of potential biomarkers'. Together they form a unique fingerprint.

Cite this